Even as the Trump administration works to implement its “most favored nation” pricing system, the U.S. government continues to advance efforts to negotiate Medicare drug prices as enabled by the Inflation Reduction Act.
Related Posts
What Health Systems Need To Know About Power and Cooling in the Age of AI
How Can Health Systems Upgrade Their Approach to Power? From a power standpoint, organizations need to make sure they have extended runtime to support […]
At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves
Listen to the article 6 min This audio is auto-generated. Please let us know if you have feedback. U.S. lawmakers clashed with Health and Human […]
What real-world data will regulators consider in Europe? – Healthcare Economist
A 2024 Data Quality Framework (DQF) from the European Medicines Agency (EMA) aims to provide some guidance for drug manufacturers. Here is a summary of […]